STAT1 and neoplasm: Compared with the baseline efficacy (MCT + anti-PD1, Dual), adding STAT1 inhibitor (Tri-therapy, Tri) significantly improved anti-tumor efficacy of anti-PD1 treatment (Dual-therapy, Dual) (Fig. 6f, p = 0.0098) with an increased percentage of tumor-associated T cells (Fig. 6g and Supplementary Fig. 6b) when compared to Dual therapy used in regimen 3.